A recent study published in ESC Heart Failure (March 4, 2025) compared initial monotherapy versus combination therapy in pulmonary arterial hypertension (PAH) patients with cardiovascular comorbidities. Results showed that the combination therapy group experienced greater improvements in functional class, BNP/NT-proBNP levels, and overall risk status compared to monotherapy patients. However, no significant differences were observed in walking distance, hospitalization rates, survival, or drug discontinuation. While suggesting potential benefits of combination therapy vs monotherapy, with good tolerability, the researchers caution that their findings may not apply to older patients with multiple comorbidities, as the matched study group was relatively younger than the overall registry population.
Read more at this link on the Wiley Online Library
Citation
Skowasch D, Pausch C, Huscher D, Pittrow D, Wede J, Kreimendahl F, Rosenkranz S, Beckmann S, Held M, Grünig E, Ghofrani HA, Klose H, Skride A, Halank M, Stadler S, Delcroix M, Vonk-Noordegraaf A, Ewert R, Kopec G, Hoeper MM, Olsson KM. Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis. ESC Heart Fail. 2025 Mar 4. doi: 10.1002/ehf2.15254. Epub ahead of print. PMID: 40037846.
